An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?
Marianna MartinoNairus AboudBeatrice LucchettiGianmaria SalvioGiorgio ArnaldiPublished in: Expert opinion on pharmacotherapy (2023)
Since there is still no standardized pharmacological approach and the superiority of one drug over another has not been established yet in the absence of comparative studies, each time clinicians' choices should be patient-tailored. Age, gender, tumor features, severity of hypercortisolism, comorbidities/complications, rapidity of action, side effects, drug-drug interactions, contraindications, availability, patients' preferences, and costs should be all considered.